|Bid||28.75 x 1200|
|Ask||31.99 x 800|
|Day's range||28.17 - 30.12|
|52-week range||13.64 - 35.93|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||11 Nov 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||29.33|
Investors who take an interest in Alector, Inc. (NASDAQ:ALEC) should definitely note that the Independent Director...
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.
AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 42 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Alector, Inc. (NASDAQ:ALEC) should be aware of the most powerful shareholder groups...